Missed the Magnificent Seven? Try buying one of these 3 Forever Shares.

If you've been paying any attention at all to the stock market buzz over the past few months, you've surely come across a lot of talk about the "Magnificent Seven" tech stocks-you know, the ones thatNvidia),Microsoft(math.) andAppleThe so-called invincible group of companies, represented by the company's founder and CEO, Mr. K. K. Kurkowski.

But as valuations of the "Magnificent Seven" soar, there is every reason for investors to look for stocks with more enduring appeal, or stocks outside the tech sector.

Thankfully, there is no shortage of good alternatives, so let's discuss three of the "Magnificent Seven" alternatives that have outperformed the broader rock over the past 12 months and have the staying power and growth potential to perpetuate in your portfolio.

1. Vertex

sayVertex Pharmaceuticals (NASDAQ: VRTX)It may come as a surprise that such a developer of rare-disease medicines could rival any of the companies in the Gorgeous Tangram, but the numbers don't lie; its stock price has risen by 33% in the last year, while Apple's has only risen by 9%.

Driving the company's success is the launch of its latest drug, a gene therapy called Casgevy, which treats both beta-thalassemia and sickle cell disease. Goon believes sales of Casgevy will help drive the company's sales to nearly $10.8 billion this year.

And as recently as 2019, the company had revenues of just $4.2 billion, all of which came from sales of cystic fibrosis drug group carbs, and has remained profitable. So there is every reason to believe that the good times will continue.

The company may soon have the opportunity to commercialize two more drugs. Its program for treating acute pain recently wrapped up a successful Phase III clinical trial, and now Vertex will apply to the regulatory body for approval of the drug by mid-2024. It will also seek approval for another cystic fibrosis treatment around the same time.

Approvals are not infallible, but the odds are good. Therefore, consider buying this stock to take advantage of its upcoming top-line growth. If you end up buying this stock, you may find that it adds value to your portfolio over time.

2. Lai Lai

come with a giftfirms(NYSE: LLY)The stock price is currently hard to beat in the biopharmaceutical space, having risen 3,35% in the last three years alone.

The stock's recent success is closely tied to its exposure to the markets for the treatment of metabolic diseases such as type 2 diabetes and obesity. Currently, the company's weight-loss drug, Zepbound, and diabetes treatment, Mounjaro, are likely to be leaders in their respective markets due to their effectiveness and increasing availability.

In the fourth quarter alone, Mounjaro's sales exceeded $2.2 billion; Koon expects total revenues of $41.6 billion in 2024, but that may only be the beginning of the growth. zepbound has been on the market for less than a year, and demand has been so strong that Eli Lilly can't produce the drug fast enough.

This makes Lilly an excellent choice, even though it is not an official member of the "G7".

3. Costco Wholesale

Costco Wholesale firms(Costco Wholesale, Nasdaq Resonance)stock (market)(Code: COST)It seems that it is not active enough to be one of the "seven giants". But that's not the case. The company's stock price has risen 1,17% in the last three years alone as it has dutifully executed its tried-and-true business model.

Costco's investment philosophy is simple. Because Costco曏 people charge an annual membership fee that gives them access to its warehouses to buy a wide variety of food stamps and other consumer goods at low prices, Costco only needs to keep its members happy in order to stay in business.

In the past 12 months, it reached $4.7 billion in total membership fees, with nearly 93% members renewing from the previous year. What's more, the number of subscribers grew by nearly 2% between 2023 and 2022.

With membership fees making up the lion's share of its net income, which exceeded $1.7 billion in the second quarter alone, the company can sell its products at razor-thin margins and still easily turn a profit. Until there is reason to believe that Costco is disappointing its customers, there is evidence that it will remain a good investment.

Should you invest $1,000 in Vertex Pharmaceuticals now?

Before buying shares of Vertex Pharmaceuticals, consider the following:

Motley Fool Stock AdvisorA team of analysts have just named what they think are the best values for investors.10Vertex Pharmaceuticals is not one of the 10 stocks listed at ....... The 10 stocks that made the list could generate huge returns in the coming years.

Stock AdvisorIt provides investors with an easy-to-understand blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. Since 2002, StockAdvisorThe service has more than doubled the return on the S&P 500 Index.

View these 10 stocks

*Stock Advisor's Circular as of March 25, 2024

Alex Carchidi owns shares of Apple, Costco Wholesale, and Microsoft.The Motley Fool holds recommendations on Apple, Costco Wholesale, Microsoft, Nvidia, and Vertex Pharmaceuticals.The Motley Fool recommends the following options: a January 2026 $395 Call Option Long on Microsoft and a January 2026 $405 Call Option Short on Microsoft.The Motley Fool has the following options: a January 2026 $395 Call Option Long on Microsoft and a January 2026 $405 Call Option Short on Microsoft. The Motley Fool recommends the following options: Microsoft January 2026 $395 Call Option Long and Microsoft January 2026 $405 Call Option Short. The Motley Fool has a disclosure policy.

Missed The Magnificent Seven? Try Buying These 3 Timeless Stocks was originally published by The Motley Fool.